Detail akcie Guardant Health Rg online

Business Summary: Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Guardant Health Inc revenues increased 30% to $700.8M. Net loss decreased 12% to $287.8M. Revenues reflect United States segment increase of 30% to $659.7M, International segment increase of 30% to $41M. Lower net loss reflects biopharmaceutical segment loss decrease of 69% to $99M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.66 to -$2.32.